Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease

被引:61
作者
Lopez, F
Parker, P
Nademanee, A
Rodriguez, RT
Al-Kadbimi, Z
Bhatia, R
Cohen, S
Falk, P
Fung, H
Kirschbaum, M
Krishnan, A
Kogut, N
Molina, A
Nakamura, R
O'Donnell, M
Popplewell, L
Pullarkat, V
Rosenthal, P
Sahebi, F
Smith, E
Snyder, D
Somlo, G
Spielberger, R
Stein, A
Sweetman, R
Zain, J
Forman, S
机构
[1] City Hope Natl Med Ctr, Div Hematol & Hematopoiet Cell Transplantat, Duarte, CA 91010 USA
[2] City Hope Kaiser Bone Marrow Transplant Program, Duarte, CA USA
[3] UCI Univ Phys & Surg Med Ctr, Orange, CA USA
关键词
transplantations; chronic graft-versus-host disease; mycophenolate mofetil;
D O I
10.1016/j.bbmt.2005.01.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Current treatment of chronic graft-versus-host disease (cGVHD) with prednisone (PSE) alone or with added cyclosporine or tacrolimus still has a very high failure and complication rate, and new treatment approaches are needed for both primary and salvage therapy. Mycophenolate mofetil (MMF) is an immunosuppressive agent currently in use for acute graft-versus-host disease prophylaxis. To determine whether MMF had activity in the treatment of cGVHD, we added MMF to standard cyclosporine, tacrolimus, and/or PSE as salvage/second-line (n = 24) or first-line (n = 10) therapy in 34 patients. Nine (90%) of 10 patients receiving first-line and 18 (75%) of 24 receiving second-line MMF therapy responded. Twelve (35%) patients had a complete remission, 15 (44%) had a partial remission, 5 (15%) had stable disease, and only 2 (6%) had progressive disease. Out of 30 patients receiving PSE, 22 (73%) were able to decrease PSE doses (median decrease of 50%; range, 25%-100%). With a median follow-up of 24 months (range, 6-28 months), 29 (85%) patients are alive. Three patients had to discontinue MMF because of abdominal cramps within 3 months of starting treatment. These data suggest that MMF is an active, well-tolerated agent in the treatment of cGVHD and may have a beneficial effect on the survival of patients with this complication. (c) 2005 American Society for Blood and Marrow Transplantation
引用
收藏
页码:307 / 313
页数:7
相关论文
共 24 条
  • [1] Abhyankar S, 1998, BLOOD, V92, p454A
  • [2] Development of a prognostic model for grading chronic graft-versus-host disease
    Akpek, G
    Zahurak, ML
    Piantadosi, S
    Margolis, J
    Doherty, J
    Davidson, R
    Vogelsang, GB
    [J]. BLOOD, 2001, 97 (05) : 1219 - 1226
  • [3] Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients
    Basara, N
    Blau, WI
    Römer, E
    Rudolphi, M
    Bischoff, M
    Kirsten, D
    Sanchez, H
    Günzelmann, S
    Fauser, AA
    [J]. BONE MARROW TRANSPLANTATION, 1998, 22 (01) : 61 - 65
  • [4] BASARA N, 1999, BLOOD, V94, pA671
  • [5] Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers.
    Bensinger, WI
    Martin, PJ
    Storer, B
    Clift, R
    Forman, SJ
    Negrin, R
    Kashyap, A
    Flowers, MED
    Lilleby, K
    Chauncey, TR
    Storb, R
    Appelbaum, FR
    Rowley, S
    Heimfeld, S
    Blume, K
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (03) : 175 - 181
  • [6] Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation
    Busca, A
    Saroglia, EM
    Lanino, E
    Manfredini, L
    Uderzo, C
    Nicolini, B
    Messina, C
    Rabusin, M
    Miniero, R
    [J]. BONE MARROW TRANSPLANTATION, 2000, 25 (10) : 1067 - 1071
  • [7] Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial
    Flowers, MED
    Parker, PM
    Johnston, LJ
    Matos, AVB
    Storer, B
    Bensinger, WI
    Storb, R
    Appelbaum, FR
    Forman, SJ
    Blume, KG
    Martin, PJ
    [J]. BLOOD, 2002, 100 (02) : 415 - 419
  • [8] FLOWERS MED, 2002, BLOOD MARROW TRANSPL, V12, P5
  • [9] Chronic graft-versus-host disease: is there an alternative to the conventional treatment?
    Gaziev, D
    Galimberti, M
    Lucarelli, G
    Polchi, P
    [J]. BONE MARROW TRANSPLANTATION, 2000, 25 (07) : 689 - 696
  • [10] Ilhan O, 1999, BLOOD, V94, p368B